Through this rule, FDA is updating the standards for FDA acceptance of data from clinical investigations conducted outside the United States to help ensure the quality and integrity of data obtained from these investigations and the protection of human subjects. In this rule, FDA is amending the regulations for PMA applications, HDE applications, IDE applications, and premarket notification submissions. As part of this rule, FDA also is amending the IDE regulations and the premarket notification regulations to address the requirements for FDA acceptance of data from clinical investigations conducted inside the United States.
News & Trends
Procurar
Recentes
- FARMACOVIGILÂNCIA avançada: ““Excelente! Organizada e abrangente !”
- Study on the deployment of AI in healthcare Final report
- Boas Práticas de Fabrico . GMP 2025: “Formação foi muito útil a nível de aplicabilidade “
- Conducting Clinical Trials With Decentralized Elements. Guidance for Industry, Investigators, and Other Interested Parties
- COMMISSION IMPLEMENTING REGULATION (EU) 2025/2086 of 17 October 2025
- Main root causes of shortages: Analysis of reported root causes during 2022 & 2023
- EUDAMED Release note v 2.18.0
- The ICH E2D(R1) Guideline reaches Step 4 of the ICH Process

